A pancreatic mass is any abnormal growth or lesion within the pancreas — ranging from entirely benign cysts that require only monitoring to pancreatic adenocarcinoma, one of the most aggressive human cancers with a 5-year survival rate of approximately 12%. Because these entities span such an enormous range of clinical urgency, accurate imaging characterization is not merely helpful — it is the pivotal step that determines whether a patient needs urgent oncologic surgery, surveillance imaging, or simple reassurance.
Pancreatic masses frequently present through their complications rather than as a primary finding. Pancreatic head tumors cause biliary duct obstruction — producing the painless progressive jaundice that is often the first signal of pancreatic cancer. Acute and chronic pancreatitis predispose to pancreatic pseudocyst formation and, in the setting of chronic pancreatitis, to adenocarcinoma development. Pancreatic neuroendocrine tumors are associated with splenic involvement and can be part of inherited syndromes including MEN1 that involve other abdominal organs. MRI with MRCP evaluates both the pancreatic mass and the entire biliary tree — including any resulting biliary obstruction — in a single comprehensive examination.
Causes
Varies by mass type.
Pancreatic adenocarcinoma — accounting for approximately 85% of pancreatic malignancies — arises from the ductal epithelium of the pancreas and is characterized by a dense desmoplastic stroma that makes it hypoenhancing on imaging, prone to early vascular invasion, and inherently resistant to many systemic therapies. Pancreatic neuroendocrine tumors (pNETs) arise from the islet cells of the endocrine pancreas — they are typically hypervascular (enhancing brightly on arterial phase MRI, in stark contrast to the hypoenhancing adenocarcinoma) and may be functioning (producing excess insulin, gastrin, glucagon, VIP, or somatostatin) or non-functioning. Cystic pancreatic lesions represent a distinct and increasingly common category: pseudocysts form from disrupted pancreatic ducts after acute or chronic pancreatitis and contain no epithelial lining; serous cystadenomas are benign microcystic tumors; mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasms (IPMNs) are mucin-producing cystic neoplasms with varying degrees of malignant potential that require careful risk stratification.
Risk factors for pancreatic cancer.
Cigarette smoking is the single largest modifiable risk factor, accounting for approximately 20–25% of pancreatic adenocarcinomas. Chronic pancreatitis — particularly hereditary pancreatitis — confers a markedly elevated lifetime risk. New-onset diabetes mellitus in adults over 50 is now recognized as a potential early marker of pancreatic cancer — approximately 1% of new adult-onset diabetes is associated with pancreatic adenocarcinoma, and unexplained new diabetes in this age group warrants pancreatic imaging. Inherited syndromes carry the highest individual risks: BRCA2 mutation carriers have a 3–10 fold increased risk; PALB2, ATM, and Lynch syndrome (MLH1, MSH2) mutations also confer elevated risk; and Peutz-Jeghers syndrome carries up to a 36% lifetime risk of pancreatic cancer. Familial pancreatic cancer (two or more first-degree relatives) qualifies for high-risk surveillance programs with annual MRI/endoscopic ultrasound beginning at age 50 or 10 years before the youngest affected relative.
Symptoms
The clinical insidiousness of pancreatic adenocarcinoma — and the reason it is so often diagnosed at an unresectable stage — is that it produces no symptoms until it has grown large enough to invade adjacent structures or metastasize. Tumors in the pancreatic head (the most common location, approximately 70% of cases) obstruct the common bile duct as it passes through the pancreatic head, producing painless progressive jaundice with dark urine, pale stools, and pruritus — often the earliest and most actionable symptom. Body and tail tumors have no bile duct to obstruct and typically present only with vague mid-abdominal or back pain (from celiac plexus invasion), unintentional weight loss, and new-onset diabetes — symptoms so nonspecific that diagnosis is frequently delayed until late-stage disease.
Functioning pancreatic neuroendocrine tumors produce distinctive clinical syndromes from hormone excess: insulinomas cause episodic hypoglycemia with confusion, sweating, and palpitations (Whipple's triad); gastrinomas (Zollinger-Ellison syndrome) cause refractory peptic ulceration and diarrhea from massive gastric acid hypersecretion; glucagonomas cause the characteristic necrolytic migratory erythema skin rash, diabetes, and weight loss; VIPomas produce profuse watery diarrhea with hypokalemia (WDHA syndrome). IPMNs may cause recurrent pancreatitis from mucin obstructing the pancreatic duct. Small cystic lesions discovered incidentally on imaging (increasingly common as abdominal CT and MRI are performed more frequently) are usually asymptomatic.
Diagnosis
Evaluation begins with blood tests: CA 19-9 (elevated in most pancreatic adenocarcinomas but lacks specificity — also elevated in biliary obstruction), chromogranin A and specific hormone levels (insulin, gastrin, glucagon) for suspected neuroendocrine tumors, and liver function tests to assess for biliary involvement. CT of the abdomen with pancreatic protocol (thin-slice arterial and portal venous phase imaging) is often the initial cross-sectional study and provides staging information. Endoscopic ultrasound (EUS) with fine-needle aspiration provides tissue diagnosis for solid masses and fluid analysis for cystic lesions.
An MRI of the abdomen with MRCP is the most comprehensive evaluation for pancreatic masses and is superior to CT for several critical tasks. MRI detects small pancreatic adenocarcinomas — particularly the T1-hypointense signal of a hypoenhancing mass against the bright normal pancreatic parenchyma on fat-suppressed T1 — with higher sensitivity than CT for lesions under 2 cm. MRCP visualizes the "double duct sign" — simultaneous dilation of both the common bile duct and the pancreatic duct — which is highly specific for pancreatic head malignancy. MRI characterizes cystic lesions with precision: IPMNs show communication with the pancreatic duct (main-duct or branch-duct types) that MRCP definitively demonstrates; MCNs appear as unilocular or macrocystic lesions without ductal communication and with an ovarian-type stroma (occurring almost exclusively in women); serous cystadenomas show a characteristic honeycomb microcystic pattern with a central stellate scar. Diffusion-weighted imaging (DWI) identifies restricted diffusion in adenocarcinoma and helps distinguish it from autoimmune pancreatitis (a benign mimicker). Vascular involvement — encasement or occlusion of the superior mesenteric artery, celiac axis, portal vein, or superior mesenteric vein — is assessed on MR angiography sequences and directly determines surgical resectability.
Classification
Pancreatic masses are classified by their histologic origin and malignant potential.
- Pancreatic ductal adenocarcinoma (PDAC): Accounts for ~85% of pancreatic cancers. Desmoplastic, hypoenhancing, and highly aggressive. Staged as resectable, borderline resectable, locally advanced (unresectable), or metastatic — determined by vascular involvement on imaging. 5-year survival approximately 12% overall; 25–30% after complete resection.
- Pancreatic neuroendocrine tumor (pNET): Hypervascular on arterial MRI phase. Graded G1–G3 by Ki-67 proliferation index. G1/G2 often slow-growing with favorable prognosis; G3 (high-grade) behaves more aggressively. Functioning pNETs produce hormone syndromes; non-functioning are often larger at diagnosis.
- IPMN (intraductal papillary mucinous neoplasm): Main-duct IPMN (pancreatic duct dilation ?5 mm) carries high malignancy risk — surgical resection recommended. Branch-duct IPMN risk-stratified by size, mural nodules, solid component, and duct dilation per Fukuoka/AGA guidelines — most small branch-duct IPMNs can be safely monitored with serial MRI.
- Mucinous cystic neoplasm (MCN): Almost exclusively in women; typically body/tail location. No ductal communication on MRCP. Surgical resection recommended due to malignant potential, regardless of size.
- Serous cystadenoma: Benign; characteristic microcystic/honeycomb appearance with central scar. No malignant potential. Observation unless symptomatic or diagnosis uncertain.
- Pancreatic pseudocyst: Fluid collection after pancreatitis; no epithelial lining. Resolves spontaneously in many cases; drainage for large symptomatic pseudocysts or infection.
- Solid pseudopapillary neoplasm (SPN): Rare; occurs predominantly in young women. Low malignant potential. Surgical resection is curative in most cases.
Treatments
Treatment is entirely determined by mass type, resectability, and patient fitness.
Surgery for adenocarcinoma: Surgical resection is the only potentially curative treatment for pancreatic adenocarcinoma. Pancreaticoduodenectomy (the Whipple procedure) is performed for tumors in the pancreatic head, uncinate process, and neck — removing the pancreatic head, duodenum, gallbladder, and distal common bile duct with reconstruction. Distal pancreatectomy with splenectomy is performed for body and tail tumors. Only approximately 15–20% of patients present with resectable disease. Borderline resectable tumors — those abutting but not encasing major vessels — are increasingly treated with neoadjuvant chemotherapy to convert to resectable status before surgery.
Chemotherapy and radiation.
FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin) and gemcitabine plus nab-paclitaxel are the standard neoadjuvant and adjuvant regimens, with FOLFIRINOX demonstrating superior survival in fit patients. Adjuvant chemotherapy for 6 months after resection significantly improves survival. For locally advanced unresectable disease, chemoradiation with gemcitabine or FOLFIRINOX-based regimens is used for local control. BRCA1/2-mutated pancreatic cancer responds to platinum-based chemotherapy and PARP inhibitors (olaparib maintenance after platinum response).
Management of neuroendocrine tumors.
Small non-functioning pNETs under 2 cm can be observed with serial MRI in selected patients given their indolent behavior. Resectable functioning pNETs and larger non-functioning tumors are surgically resected. Advanced pNETs are managed with somatostatin analogs (octreotide LAR, lanreotide — which reduce hormone secretion and have antiproliferative effects), everolimus (mTOR inhibitor), sunitinib (VEGFR inhibitor), and peptide receptor radionuclide therapy (PRRT with lutetium-177 DOTATATE) for somatostatin receptor-positive tumors.
Management of cystic lesions.
Main-duct IPMNs are resected given their high malignancy risk. Branch-duct IPMNs are managed per Fukuoka or AGA guidelines: lesions with high-risk stigmata (mural nodule, solid component, main duct involvement, obstructive jaundice) are resected; others are monitored with MRI at 6–12 month intervals initially. MCNs are surgically resected. Serous cystadenomas are observed unless symptomatic. Pseudocysts are drained endoscopically (EUS-guided cystogastrostomy) or surgically when large, infected, or causing symptoms.
Supportive care.
Pancreatic exocrine insufficiency — present in most patients with advanced pancreatic disease — requires pancreatic enzyme replacement therapy (PERT) with every meal. Celiac plexus neurolysis provides effective pain control for unresectable tumors with celiac invasion. Biliary stenting relieves obstructive jaundice in unresectable cases. Meticulous glucose monitoring and insulin adjustment are required as pancreatic endocrine function is compromised.
Get an MRI to Confirm Your Diagnosis
Before surgical planning or starting treatment, a clear MRI diagnosis ensures the right path forward. First Look MRI offers self-pay Abdomen MRI scans — no doctor's order or insurance required — at our locations in Georgia, Texas, and Colorado.